China’s NMPA clears Akeso’s AK158D1 for Phase I trial in solid tumours

​

Akeso has received clearance from the CDE under China’s NMPA to begin a Phase I trial of AK158D1 for patients with advanced malignant solid tumours.

The post China’s NMPA clears Akeso’s AK158D1 for Phase I trial in solid tumours appeared first on Hospital Management.

 

Back to the Featured Stories
China’s NMPA clears Akeso’s AK158D1 for Phase I trial in solid tumours

Featured Stories

FDA clears Neptune Medical’s Triton 1 system for colon procedures
Roche agrees to $1bn deal with Dualitas for bispecific antibody research
FDA clears Medtronic’s LigaSure RAS Maryland device
SpliSense begins Phase IIb SPL84 trial for cystic fibrosis
Viatris’ Wakix receives Japanese approval to treat OSAS and narcolepsy

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.

Contact Us